Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics

Title:Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics

Volume: 30 Issue: 21

Author(s): Ramin Raoufinia, Hamid Reza Rahimi, Mahla Abbaszadeh, Aida Gholoobi, Ehsan Saburi, Farhad Fakoor, Hawraa Ibrahim Alshakarchi, Ibrahim Saeed Gataa, Seyed Mahdi Hassanian, Gordon A. Ferns, Majid Khazaei and Amir Avan*

Affiliation:

• Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
• Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
• Faculty of Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane 4059, Australia

Keywords: Personalized medicine, cardiovascular diseases, FDA-approved interventions, clinical pharmacognetics, quality of life, heart conditions.

Abstract: Cardiovascular diseases place a considerable burden on global health systems, contributing to high rates of morbidity and mortality. Current approaches to detecting and treating Cardiovascular Diseases (CVD) often focus on symptomatic management and are initiated after the disease has progressed. Personalized medicine, which tailors medical interventions to individual characteristics, has emerged as a promising strategy for improving cardiovascular health outcomes. This article provides an overview of personalized medicine in the context of CVD, with a specific emphasis on FDA-approved interventions. It explores the potential benefits, challenges, and future directions of personalized medicine in cardiovascular disorders. By reviewing the advancements in this field, this article underscores the importance of early detection, intervention, and innovative treatment options in reducing the impact of CVD on individuals and society.

Cite this article as:

Raoufinia Ramin, Rahimi Reza Hamid, Abbaszadeh Mahla, Gholoobi Aida, Saburi Ehsan, Fakoor Farhad, Alshakarchi Ibrahim Hawraa, Gataa Saeed Ibrahim, Hassanian Mahdi Seyed, Ferns A. Gordon, Khazaei Majid and Avan Amir*, Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics, Current Pharmaceutical Design 2024; 30 (21) . https://dx.doi.org/10.2174/0113816128309440240427102903